MedPath

Enteral Nutrition in Acute Pancreatitis

Phase 4
Completed
Conditions
Acute Pancreatitis
Interventions
Dietary Supplement: Enteral nutrition
Registration Number
NCT01965873
Lead Sponsor
University Hospital Rijeka
Brief Summary

The purpose of this prospective randomised clinical trial is to compare beneficial and harmful effects of the use enteral nutrition versus a nil-by-mouth and intravenous fluid replacement principle of treatment in patients with moderate to severe acute pancreatitis (AP).

The hypothesis:

* enteral nutrition is no significantly better compared with the nil-by-mouth principle regarding mortality, incidence of local and systemic complications, length of hospital stay, and intensity of the inflammatory response in patients with moderate to severe AP

* enteral nutrition has the same safety as nil-by-mouth principle in patients with moderate to severe AP

Detailed Description

Patients with first attack of AP irrespective of etiology will be enrolled in the study, if they are eligible according to the following criteria:

Inclusion criteria:

* onset of symptoms consistent with AP within 72 hours before admission to the hospital

* an 3-fold elevation of serum amylase or serum lipase over the upper limit of normal

* APACHE II score 6 or more

* a signed informed consent

Exclusion criteria:

* patients \< 18 years of age

* pregnant and breastfeeding women

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
214
Inclusion Criteria
  • onset of symptoms consistent with AP within 72 hours before admission to the hospital
  • an 3-fold elevation of serum amylase or serum lipase over the upper limit of normal
  • APACHE II score 6 or more
  • a signed informed consent
Exclusion Criteria
  • patients < 18 years of age
  • pregnant and breastfeeding women

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Enteral nutritionEnteral nutritionIn the enteral nutrition group a nasojejunal feeding tube will be placed via esophagogastroduodenoscopy and the position confirmed radiographically. Nutritional support will be started within 24 hours of enrollment, supplying daily 105 kJ (25 kcal)/kg, and 1.5 g/kg of protein based on ideal body weight. An elemental product for enteral nutrition will be infused at a rate of 25 ml/h, and increased by 10 ml/h every 6 hours, until the target rate of 100 ml/h will be achieved within 24-48 hours.
Primary Outcome Measures
NameTimeMethod
SIRS (Systemic Inflammatory Response Syndrome)4 weeks
Secondary Outcome Measures
NameTimeMethod
Inflammatory response (CRP on the first and third day)First and third day of admission
All-cause mortality4 weeks
Local complications (pancreatic necrosis, fluid collections, pseudocyst, abscess)4 weeks
Other infections4 weeks
Organ failure (cardiovascular, respiratory, renal)4 weeks
Local septic complications4 weeks
Adverse events4 weeks
Length of hospital stay4 weeks
© Copyright 2025. All Rights Reserved by MedPath